Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02304484 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 770
- Enrollment target
NCT02304484 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 770 participants.
The verdict
NCT02304484, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 770 participants
- Enrollment target
Study Summary
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
Interventions
- BIOLOGICAL Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 770 participants |
| Start Date | 2014-11-24 |
| Est. Completion | 2018-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02304484
The ClinicalTrials.gov registry entry for NCT02304484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 770 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evolocumab is the first listed.
NCT02304484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02304484 about?
NCT02304484 is a clinical study titled "Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab". The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
What is the current status of trial NCT02304484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 770 participants. The study started on 2014-11-24. Estimated completion is 2018-03-09.
What interventions are being tested in trial NCT02304484?
The interventions under investigation include: Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02304484?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.